The Future of Stem Cell Treatments
Those who choose to invest in cord blood, cord tissue, and placental tissue banking are not just investing in the medicine of today—they are recognizing the future of stem cell and regenerative medicine.
The treatment potential of hematopoietic stem cells (HSCs) is far from exhausted. There are promising trials underway (over 1300 of them!) with these cells that have the potential to continue the revolution in treatment that began with the first successful stem cell transplants. Trials and tests are underway to address medical conditions such as:
But the mesenchymal stem cells (MSCs) found in abundance in cord tissue and placental tissue are also the subject of serious research. Because these cells are capable of differentiating into multiple types of cells and tissues, including organ and muscle tissue, skin, bone, cartilage, and fat cells, many leading researchers and scientists believe that they will truly revolutionize medical practice.
MSC therapies have not been FDA-approved for treatment yet, but they have been approved for treatment in the European Union, Canada, and Australia and there are more than 300 major MSC clinical trials underway worldwide focusing on a wide range of medical conditions, including:
At Americord, we are committed to partnering with physicians and scientists to help people live healthier, longer lives. It starts with our Executive Medical Director, leading hematologist, pediatric oncologist, and blood and stem cell banking expert Dr. Robert Dracker. Under his guidance, we are dedicated to stem cell banking innovations that will allow our customers to benefit from the great work being accomplished by researchers around the world.